You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of the UValidate platform for the profiling of topically applied chemical agents.

    SBC: AMELIA TECHNOLOGIES LLC            Topic: R

    Project Summary Skin is the first line of defense against the outside environment. When the skin barrier is breached by UV irradiation (UVR) or toxic chemicals, living cell layers including epidermal keratinocytes, melanocytes and dermal fibroblasts are subjected to DNA damage. If unrepaired, this damage can lead to photoaging and cutaneous carcinogenesis. In fact, skin cancer is by far the most c ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Development of (R,S')-MNF as a dual-targeted therapy for pancreatic cancer

    SBC: PAZ PHARMACEUTICALS LLC            Topic: NCI

    Summary Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the U.S. with a 5-year survival rate of andlt;9%. The poor prognosis is partially due to resistance to standard of care treatments including gemcitabine (Gem) and Gem+nab-paclitaxel (n-PTX). The transcription factors HIF-1α and c-MYC are at the center of the mechanisms producing Gem and n-PTX resistance ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Ophthalmic Product for Corneal Infections and Injuries

    SBC: BIOLYTX PHARMACEUTICALS CORP            Topic: NEI

    Biolytx Pharmaceuticals Corp. is developing a peptide, BP001, derived from the human endogenous host defense protein CAP37, as a novel multi-target ophthalmic product for corneal infections and injuries. The standard-of-care for corneal infections is topical administration of antibiotics that may be accompanied by topical steroids, to limit the destructive effect of the resulting corneal inflammat ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?

    SBC: Mabloc, LLC            Topic: NIAID

    Abstract PROJECT SUMMARY/ABSTRACT The recent groundbreaking experiment using a single neutralizing monoclonal antibody (nmAb) to reduce the death rate in Ebola virus (EBOV)-infected individuals highlights the importance of this class of drug in the treatment of infectious disease. In August 2019, Dr. Anthony Fauci announced that administration of mAb114 had reduced the death rate from 70% to appro ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Disposable, medication-integrated tactile and motion sensor for glaucoma therapy compliance improvement

    SBC: RETINAL CARE INC            Topic: N

    ABSTRACT Glaucoma is the leading cause of irreversible blindness in the world. The number of people with primary open angle glaucoma is expected to exceed 100 million by 2040. The first-line therapy for glaucoma treatment is patient-administered hypotensive medication delivered topically via an eye drop. However, studies have consistently shown that patients rarely adhere to dosing recommendations ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Analytics-Based Platform for Diabetic Retinopathy Care Management

    SBC: RETINAL CARE INC            Topic: NEI

    ABSTRACT Despite the overefficacy of diabetic retinopathyDRtreatmentit continues to be the leading cause of blindness in working age AmericansOvermillion adults in the US have diabetesOf thesewill develop DR andwill develop vision threatening DRVTDRCurrentlyless than half of all patients with diabetes receive the recommended annual dilated eye exam andof those diagnosed with VTDRonlyundergo timely ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Targeted Therapy for Myasthenia Gravis

    SBC: ARC Biotechnology LLC            Topic: NINDS

    Myasthenia gravis is a severe neuromuscular disease primarily caused by complement activating autoantibodies directed towards the skeletal muscle acetylcholine receptor. Present treatments are ineffectiveand uniformly have adverse effects, which negatively impact quality of life. Despite being a rare disease, myasthenia gravis is a costly one with a hospitalization expense of half a billion dollar ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Automated Intestinal Electrical Stimulation for Diabetes

    SBC: TRANSTIMULATION RESEARCH INC            Topic: 200

    Diabetes affects more than 9% of Americans and costs over $300 billion in 2017 in USA. Medical therapies have limitations in treating diabetic patients with obesity due their common side effects of weight gain. Bariatric surgery has been proposed for treating diabetic patients with promising outcomes. In this project, we propose a novel method of intestinal electrical stimulation (IES) for treatin ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of an M Protein-Deficient Respiratory Syncytial Virus Vaccine for Aerosolized Vaccination of the Lung

    SBC: HEARTLAND VACCINES LLC            Topic: NIAID

    Project Summary/Abstract Respiratory syncytial virus (RSV) is a major respiratory pathogen in human infants and elderly individuals. RSV infection is the principal cause of hospitalization of infants, and is a leading cause of infant mortality worldwide. In elderly adults, RSV infection accounts for 10-15,000 deaths annually in the US alone. Despite the high impact of RSV, there is presently no li ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. C.A.R.E.S.: A Mobile Health Program for Alcohol Risk Reduction for an Under-Served College Population

    SBC: LIVE INSPIRED LLC            Topic: 550

    Excessive alcohol use is the third-leading preventable cause of death in the U.S. with young adults ages 18-29 showing the highest rates of hazardous alcohol use. Community colleges serve over 12 million students, comprising 45% of all U.S. college students. Community college students (CCS) show rates of heavy alcohol use similar to students at traditional four-year residential (FYR) colleges, but ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government